Literature DB >> 15196820

Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by NMSO3 in tissue culture assays.

Philip R Wyde1, Edina H Moylett, Srikrishna N Chetty, Alan Jewell, Terry L Bowlin, Pedro A Piedra.   

Abstract

Human metapneumovirus (hMPV) is a recently elucidated respiratory virus pathogen for which there are no agents currently licensed to prevent or treat infections caused by it. However, NMSO3 has been reported to inhibit replication of human respiratory syncytial virus (hRSV), a virus that is closely related to hMPV, both in vitro in tissue culture cells and in vivo in cotton rats. For this reason, experiments were performed to compare the antiviral activity of NMSO3 against both hRSV and hMPV in tissue culture-based assays. Heparin and ribavirin, two other compounds known to inhibit hRSV, and two other paramyxoviruses, human parainfluenza virus type 3 (PIV3) and measles virus (MV), were included in these tests for comparison. All three compounds significantly inhibited the replication of subtype A and B strains of hRSV and serotypes 1 and 2 hMPV. However, unlike ribavirin, NMSO3 and heparin inhibited only hMPV and hRSV and not PIV3 or MV. Also unlike ribavirin, the activity of the two sulfated molecules was most effective if these materials were present during virus attachment and penetration of host cells. Interestingly, NMSO3, but not heparin, was able to limit secondary infection and spread of both viruses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15196820     DOI: 10.1016/j.antiviral.2004.02.006

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  20 in total

Review 1.  New Approaches for Immunization and Therapy against Human Metapneumovirus.

Authors:  Sherry C Wen; John V Williams
Journal:  Clin Vaccine Immunol       Date:  2015-06-10

Review 2.  To assemble or not to assemble: The changing rules of pneumovirus transmission.

Authors:  Nicolás Cifuentes-Muñoz; Rebecca Ellis Dutch
Journal:  Virus Res       Date:  2019-03-05       Impact factor: 3.303

3.  Human metapneumovirus (HMPV) binding and infection are mediated by interactions between the HMPV fusion protein and heparan sulfate.

Authors:  Andres Chang; Cyril Masante; Ursula J Buchholz; Rebecca Ellis Dutch
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

Review 4.  Targeting RSV with vaccines and small molecule drugs.

Authors:  Heather M Costello; William C Ray; Supranee Chaiwatpongsakorn; Mark E Peeples
Journal:  Infect Disord Drug Targets       Date:  2012-04

Review 5.  Epidemiology of human metapneumovirus.

Authors:  Jeffrey S Kahn
Journal:  Clin Microbiol Rev       Date:  2006-07       Impact factor: 26.132

6.  Role of cellular glycosaminoglycans and charged regions of viral G protein in human metapneumovirus infection.

Authors:  Sutthiwan Thammawat; Tania A Sadlon; Peter G Hallsworth; David L Gordon
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

7.  DC-SIGN and L-SIGN Are Attachment Factors That Promote Infection of Target Cells by Human Metapneumovirus in the Presence or Absence of Cellular Glycosaminoglycans.

Authors:  Leah Gillespie; Kathleen Gerstenberg; Fernanda Ana-Sosa-Batiz; Matthew S Parsons; Rubaiyea Farrukee; Mark Krabbe; Kirsten Spann; Andrew G Brooks; Sarah L Londrigan; Patrick C Reading
Journal:  J Virol       Date:  2016-08-12       Impact factor: 5.103

Review 8.  Human metapneumovirus in adults.

Authors:  Lenneke E M Haas; Steven F T Thijsen; Leontine van Elden; Karen A Heemstra
Journal:  Viruses       Date:  2013-01-08       Impact factor: 5.048

9.  Effect of NMSO3 treatment in a murine model of human metapneumovirus infection.

Authors:  Leanne Spetch; Terry L Bowlin; Antonella Casola
Journal:  J Gen Virol       Date:  2008-11       Impact factor: 3.891

10.  Diversity in glycosaminoglycan binding amongst hMPV G protein lineages.

Authors:  Penelope Adamson; Sutthiwan Thammawat; Gamaliel Muchondo; Tania Sadlon; David Gordon
Journal:  Viruses       Date:  2012-12-14       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.